KRAS mutations are notorious drivers in approximately 30% of all human cancers, with an overwhelming 90% incidence in pancreatic ductal adenocarcinoma (PDAC), a malignancy characterized by dismal prognosis and limited treatment options. KRAS inhibitors have been hailed as potential game-changers, yet their clinical efficacy is frequently undermined by acquired drug resistance. This research addresses a critical gap: the role of metabolic rewiring and mitochondrial quality control, particularly mitophagy, in mediating resistance to KRAS-targeted therapies.

The study centers on the observation that KRAS inhibitors, specifically MRTX1133 targeting the KRAS(G12D) mutant and the pan-RAS inhibitor RMC-6236, lead to a significant reduction in ATP citrate lyase (ACLY) expression and consequently decrease cytosolic AcCoA levels in both murine KPC cells and human PDAC AsPC-1 cells harboring KRAS(G12D) mutations. This metabolic suppression initiates a cascade culminating in elevated mitophagy, a selective autophagic process for mitochondrial turnover. Importantly, the induction of mitophagy by KRAS inhibition was effectively antagonized by exogenous acetate supplementation, underscoring the centrality of the ACLY-AcCoA axis in controlling this process.

Delving deeper, the researchers demonstrated that mitophagy triggered by KRASi is strikingly dependent on NLRX1, a mitochondrial NOD-like receptor previously implicated in innate immune signaling and mitochondrial homeostasis. NLRX1-deficient cells exhibited a near-complete abrogation of KRASi-induced mitophagy, illuminating its indispensable role as a mediator of mitochondrial quality control in this context. The absence of NLRX1 not only hindered mitophagy but also resulted in pronounced accumulation of reactive oxygen species (ROS) and heightened cellular oxidative stress, as evidenced by increased NADP⁺/NADPH ratios.

The functional consequences of these molecular events were profound. NLRX1 deficiency sensitized cancer cells to KRAS inhibition, augmenting cytotoxicity in both murine and human KRAS-mutant PDAC and lung cancer models. This finding was further bolstered by experiments involving the antioxidant N-acetyl-L-cysteine (NAC), which rescued the viability of NLRX1-deficient cells exposed to KRASi by mitigating oxidative stress. It became evident that the mitophagy pathway represents a cellular defensive maneuver that mitigates ROS-induced damage to sustain tumor cell survival during KRAS-targeted therapy.

Complementing the in vitro analyses, in vivo studies employing a subcutaneous KPC tumor model in NSG mice cemented the therapeutic relevance of the ACLY–AcCoA–NLRX1 axis. Mice receiving the KRAS inhibitor MRTX1133 exhibited notable tumor regression, an effect amplified in the absence of NLRX1. Moreover, immunoblot and histological analyses revealed that while Acly suppression occurred uniformly across conditions, mitochondrial protein levels—indicative of mitophagy—were preserved in NLRX1-deficient tumors, affirming the disrupted mitophagic response. Consistently, ROS levels were reduced in control tumors following KRASi but escalated in NLRX1-lacking specimens, reinforcing the interplay between mitophagy, redox balance, and therapy resistance.

These revelations shift the paradigm by identifying mitophagy not merely as a housekeeping process but as a vital resistance mechanism exploited by cancer cells under pharmacologic assault. The study’s insights suggest that targeting the metabolic regulation of mitophagy—specifically through the ACLY-AcCoA-NLRX1 signaling axis—may enhance the efficacy of KRAS inhibitors and suppress tumor adaptation.

Intriguingly, this research also reports synergistic antitumor effects when combining KRAS inhibitors with mitophagy inhibitors like Mdivi-1, which exacerbates mitochondrial dysfunction and oxidative stress in cancer cells. This dual targeting strategy presents a compelling therapeutic avenue, potentially circumventing the resilience conferred by mitophagy-mediated mitochondrial clearance.

From a mechanistic viewpoint, the intimate connection between decreased ACLY activity and mitophagy induction underscores the broader concept that metabolic state functions as a signaling nexus. Cytosolic AcCoA emerges as more than a metabolic intermediate; it acts as a signaling metabolite communicating cellular energy and nutrient status to the mitophagy machinery. This axis elegantly illustrates how metabolic rewiring can intersect with organelle quality control to govern cell fate decisions during oncogenic stress.

Beyond immediate therapeutic implications, these findings raise significant questions about mitophagy’s role across diverse KRAS-mutant tumor types and contexts of therapy resistance. As chronic KRAS inhibition becomes more prevalent in clinical oncology, understanding how tumor cells engage mitochondrial quality control pathways could guide the design of combinatorial regimens that preempt or reverse resistance.

Moreover, this study highlights the vital importance of ROS homeostasis in malignancies driven by KRAS mutations. The intricate balance between mitochondrial removal and redox signaling revealed here may represent a universal vulnerability exploitable across cancers characterized by oxidative stress adaptations.

In conclusion, the elucidation of the ACLY–AcCoA–NLRX1 axis as a regulator of mitophagy in KRAS inhibitor-mediated drug resistance broadens the framework of cancer metabolism and organelle dynamics in oncogenesis. It opens exciting pathways for innovative treatments that disrupt tumor adaptive mechanisms, potentially transforming outcomes for patients afflicted with some of the deadliest KRAS-driven cancers.

Subject of Research:
KRAS-mutant cancer metabolism, mitophagy, and drug resistance mechanisms

Article Title:
Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy

Article References:
Zhang, Y., Shen, X., Shen, Y. et al. Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy. Nature (2025). https://doi.org/10.1038/s41586-025-09745-x

Image Credits: AI Generated

DOI:
https://doi.org/10.1038/s41586-025-09745-x

The challenge with existing intravenous mRNA delivery systems has long been their inability to selectively localize therapeutic agents to the pancreas. Most current methods rely on systemic circulation that tends to scatter administered drugs widely throughout various tissues, diminishing efficacy and increasing unwanted off-target effects. The research team at UNLV, led by Professor Chandrabali Bhattacharya, successfully circumvented this limitation by engineering a novel class of lipid nanoparticles, which they have trademarked as ENDO (Endogenous Targeting Lipid Nanoparticles). Unlike conventional nanoparticles that follow non-specific biodistribution patterns, ENDO particles harness the body’s endogenous material transport mechanisms to home in on the pancreas with remarkable specificity.

A key insight driving this technology is the exploitation of Vitamin D receptors found on the surface of certain cells. These receptors, though distributed widely in the body, are present in particular conformation and density on pancreatic cells’ surfaces, making them ideal “coordinates” for nanoparticle targeting. By incorporating vitamin D or similar biologically relevant molecules into the lipid nanoparticle formulation, the research team was able to program these particles to interact selectively with Vitamin D receptors, effectively commandeering the body’s natural transport pathways to direct their cargoes to the pancreas.

This targeted delivery system was shown to achieve a phenomenal selectivity rate of approximately 99 percent for the pancreas following systemic intravenous injection. To put this achievement into perspective, no previous material or delivery vector had demonstrated such a high degree of natural pancreatic tropism upon intravenous administration, marking a decisive milestone in nanomedicine. This breakthrough is not merely a proof-of-concept but represents a scalable and adaptable platform for the systemic administration of nucleic acid-based therapies to an organ notoriously difficult to reach.

The implications of this targeted mRNA delivery technology are immense, particularly for chronic and life-altering conditions such as diabetes. Current insulin therapies require lifelong administration and continuous monitoring, often burdening patients with recurrent costs and variability in glucose control. mRNA therapeutics delivered directly to pancreatic cells could potentially modulate or restore endogenous insulin production, thereby mitigating disease progression. Lead author Ivan Isaac emphasizes that this innovative therapy could slow down or even reverse beta cell loss—the hallmark of diabetes progression—reducing the need for frequent injections and offering patients a significantly improved quality of life.

Beyond diabetes, the ENDO platform holds promise in addressing pancreatic cancer, a disease with notoriously poor prognosis and limited treatment options due to the pancreas’ relative inaccessibility. By enabling precise delivery of mRNA molecules encoding for tumor suppressors or immune modulators, this technology could revolutionize how oncologists approach pancreatic tumors, potentially enhancing therapeutic efficacy while minimizing systemic toxicities associated with chemotherapy or radiation.

The researchers achieved this feat by meticulous reengineering of the lipid nanoparticle composition. Incorporating endogenous molecules such as vitamin D not only improved targeting specificity but also improved biocompatibility and reduced immunogenicity. This endogenous biomimicry enables the nanoparticles to evade rapid clearance by the immune system, prolonging their circulation time and enhancing tissue uptake. Through extensive in vitro and in vivo studies, the team demonstrated the critical role of the Vitamin D receptor-mediated route, confirming that blocking these receptors significantly reduces pancreatic nanoparticle uptake, thereby validating the targeting mechanism.

This accomplishment also marks a critical conceptual advancement by breaking the existing paradigm that liver-targeted delivery is often the default in mRNA therapies due to the organ’s natural propensity to sequester nanoparticles. By devising a strategy to bypass the liver and enrich therapeutic payloads in the pancreas, the research paves the way for expanding mRNA therapeutics beyond hepatic applications to other vital organs that have remained elusive targets until now.

UNLV’s study further underlines the versatile nature of the ENDO system, which the researchers are already customizing for delivery to other challenging tissues such as the brain and heart. These organs similarly pose formidable barriers for drug delivery due to protective anatomical features like the blood-brain barrier and complex vascularization. The researchers believe that by adjusting ligand composition and nanoparticle architecture, this platform could eventually offer unprecedented precision in treating neurodegenerative disorders, cardiovascular diseases, and beyond.

Ivan Isaac, a graduate researcher deeply involved in the development of ENDO, envisions a future where precision nanomedicine fundamentally reshapes therapeutic regimens. Emphasizing safety and patient tolerance, he expects next-generation delivery platforms to reduce immune activation and side effects often associated with RNA vaccines and therapies, thereby broadening the clinical applicability of mRNA technologies. This could herald a new era where treatment regimens become less frequent, less invasive, and more effective.

Commercialization efforts are underway in collaboration with UNLV’s Office of Economic Development, reflecting confidence in the technology’s translational potential. The ability to reliably produce and scale ENDO nanoparticles could prompt rapid adoption in pharmaceutical pipelines, encouraging partnerships aimed at accelerating clinical trials and eventual FDA approval. The team remains committed to advancing this platform from bench to bedside, anticipating that their innovation will serve as a foundational blueprint for precision organ-targeted therapeutics.

Professor Bhattacharya underscores the monumental nature of this achievement, framing it as a foundational stepping stone that can catalyze a paradigm shift in drug delivery science. By bridging molecular biology, chemistry, and nanotechnology, the ENDO system exemplifies the convergence of interdisciplinary research driving forward the future of personalized medicine. The prospect of safer, more effective, and organ-specific therapies no longer seems distant but imminently achievable.

In conclusion, this transformative research signifies a remarkable stride toward overcoming one of the most persistent challenges in drug delivery — the ability to selectively and systemically target therapeutics to specific internal organs. The successful routing of mRNA to the pancreas via endogenous Vitamin D receptor pathways heralds a new dawn in the treatment of pancreatic diseases and opens vast unexplored avenues for mRNA-based interventions that could impact a plethora of medical conditions in the years ahead.

Subject of Research: Cells
Article Title: Reengineering Endogenous Targeting Lipid Nanoparticles (ENDO) for Systemic Delivery of mRNA to Pancreas
News Publication Date: 12-Jun-2025
Web References: https://advanced.onlinelibrary.wiley.com/doi/10.1002/adma.202507657
References: Bhattacharya, C., Isaac, I., Patel, L., Tran, N., Singam, A., Yun, D.S., Guha, P., Park, S. (2025). Reengineering Endogenous Targeting Lipid Nanoparticles (ENDO) for Systemic Delivery of mRNA to Pancreas. Advanced Materials.
Keywords: Autoimmune disorders, Type 1 diabetes, Type 2 diabetes, Insulin, Diabetes, Diseases and disorders, Pancreatic cancer, Pancreatitis